Archives

by in
Entry Author Date Location
The Road to Predictable Innovation: Genomics in Drug R&D 12/10/12 Boston
Amgen Acquires DeCode Genetics, the Once-Fallen Star, for $415M 12/10/12 National
Where’s the Can-Do Spirit in Biotech? It’s Alive, Deep Down 12/03/12 National
Xconomist of the Week: NPS’s Francois Nader Shares Lessons Learned 10/25/12 New York
Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker 10/03/12 Seattle
The Reproducibility Initiative: A Good Idea in Theory that Won’t Work in Practice 10/02/12 Seattle
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Bayer, Onyx Cancer Drug Wins FDA Approval Ahead of Schedule 09/27/12 San Francisco
Zymeworks Hits Antibody Drug Milestone For Merck, Raises $11M 09/06/12 Seattle
Would Longer Drug Patents Really Lead to Lower Drug Prices? 09/05/12 Seattle
Fearless Football and Biotech Picks For Fall 2012 09/04/12 National
A Lonely Voice Asking Tough Questions on Cancer Cost-Effectiveness 07/30/12 National
NPS Rejiggers Amgen Deal, Sees $75M Extra Cash 07/02/12 New York
NPS Rallies as Good News Flows for Two Rare-Disease Drugs 06/25/12 New York
Clash of the BioPharma Titans Looms Over Biosimilars 06/25/12 National
Kineta, Playing for Bunt Singles, Builds a Biotech Company Without VC Bucks 06/06/12 Seattle
Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers 05/21/12 National
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Eleven Biotherapeutics Raises $20M to Advance Dry-Eye Drug 05/08/12 Boston
Biotech IPOs Start to Show Some Modest Signs of Life 04/30/12 National
George Rathmann, Founding CEO of Amgen and Icos, Dies at 84 04/23/12 Seattle
What Are the Hottest Targets in Biotech Today? 04/23/12 National
Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs 04/19/12 Seattle
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
BioPharma Needs A Safe, Reliable Way To Repair Broken Genes 04/11/12 Seattle
Biotech Can’t Sidestep Cost-Effectiveness Anymore 04/02/12 National
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen 03/27/12 San Francisco
CytomX Therapeutics Seeks to One-Up Lilly, Amgen Cancer Drugs 03/02/12 San Francisco
Xconomist of the Week: Roger Perlmutter’s Parting Thoughts on Amgen 03/01/12 National
FDA vs. Drug Ads: Cut the Kids and Dogs, Spell Out Side Effects 02/06/12 National
Page 2 of 11 « previous page · next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Venture Funding Slows as VC Industry Contracts, & Top 10 Deals List
  2. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  3. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  4. Do You Need an Extended Warranty? Do the Math, Says SquareTrade
  5. When iMovie Isn’t Enough, Amateur Video Producers Can Go Pro

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.